论文部分内容阅读
免疫逃逸近期被认为是肿瘤进展的重要角色。程序性死亡配体-1(Programmed death ligand-1,PD-L1)是近年发现的具有负性免疫调节作用的B7家族的成员，PD-L1与表达于T淋巴细胞表面的受体程序性死亡受体-1（Programmed death 1,PD-1）结合后发挥抑制肿瘤免疫及促进肿瘤进展的作用.PD-L1被发现在多种肿瘤细胞中高表达并与预后负相关。抗PD-L1/PD-1抗体应用于肿瘤的治疗并带来显著效果。但只有部分患者治疗有效。因此，进一步了解PD-L1表达调控将有利于抗PD-L1/PD-1抗体治疗的改进。本文就PD-L1表达调控的研究进展进行总结概括。“,”The recent immune escape is considered to be an important role in tumor progression, programmed death ligand-1 (PD-L1) is a member of the recently discovered has a negative regulatory role of immune B7 family, and the expression of PD-L1 receptor in process T lymphocyte death receptor-1 (PD-1) after the combination of inhibit tumor immunity and promote tumor progression of.PD-L1 was found high expression in tumor cells and negative correlation with prognosis. The treatment of anti PD-L1/PD-1 antibody used in tumor and bring significant results. But only a part of patients with effective treatment. Therefore, further understanding of the regulation of PD-L1 expression, there will be conducive to improvement of anti PD-L1/PD-1 in this paper, PD-L1 antibody treatment. The expression of progress in regulation are summarized.